9β-PGD1 Compounds

ABSTRACT

Prostaglandin analogs with the following cyclopentane ring structure: ##STR1## are disclosed along with intermediates useful in their preparation and processes for their preparation. These analogs are useful for the same pharmacological purposes as the prostaglandins, particularly and especially as blood platelet aggregation inhibitors.

The present application is a divisional application of Ser. No. 614,242, filed Sept. 17, 1975, now issued as U.S. Pat. No. 4,016,184, on Apr. 5, 1977.

The present invention relates to prostaglandin analogs for which the essential material constituting a disclosure therefor is incorporated by reference here from U.S. Pat. No. 4,016,184, issued Apr. 5, 1977. 

I claim:
 1. A prostaglandin analog of the formula ##STR2## wherein Y is cis--CH═CH-- or trans --CH═CH--; wherein m is 1 to 5, inclusive;Wherein M₁ is ##STR3## wherein R₅ and R₆ are hydrogen or methyl, with the proviso that one of the R₅ and R₆ is methyl only when the other is hydrogen; Wherein L₁ is ##STR4## or a mixture of ##STR5## wherein R₃ and R₄ are hydrogen, methyl, or fluoro, being the same or different, with the proviso that one of R₃ and R₄ is fluoro only when the other is hydrogen or fluoro; Wherein R₁ is hydrogen, alkyl of one to 12 carbon atoms, inclusive, cycloalkyl of 3 to 10 carbon atoms, inclusive, aralkyl of 7 to 12 carbon atoms, inclusive, phenyl, phenyl substituted with one, two, or three chloro or alkyl of one to 3 carbon atoms, inclusive, or a pharmacologically acceptable cation; and Wherein Z₇ is

    (1) --(CH.sub.2).sub.3 --(CH.sub.2).sub.g --CF.sub.2 --CF.sub.2 --, or

    (2) --(CH.sub.2).sub.3 --(CH.sub.2).sub.g --CH.sub.2 --,

wherein g is 1, 2, or
 3. 2. A compound according to claim 1, wherein M₁ is ##STR6##
 3. A compound according to claim 1, wherein M₁ is ##STR7##
 4. A compound according to claim 3, wherein Y is cis--CH═CH--.
 5. A compound according to claim 4, wherein m is
 3. 6. A compound according to claim 5, wherein g is
 3. 7. 2a,2b-Dihomo-9β-15-epi-cis-13-PGD₁, a compound according to claim
 6. 8. A compound according to claim 5, wherein g is
 1. 9. 2,2-Difluoro-9β-15-epi-cis-13-PGD₁, a compound according to claim
 8. 10. 9β-15-epi-cis-13-PGD₁, a compound according to claim
 8. 11. A compound according to claim 3, wherein Y is trans--CH═CH--.
 12. A compound according to claim 11, wherein m is
 3. 13. A compound according to claim 12, wherein Z₇ is --(CH₂)₃ --(CH₂)_(g) --CF₂ --.
 14. A compound according to claim 13, wherein g is
 3. 15. A compound according to claim 13, wherein g is
 1. 16. A compound according to claim 15, wherein R₅ and R₆ are both hydrogen.
 17. A compound according to claim 16, wherein R₃ and R₄ are both hydrogen.
 18. 2,2-Difluoro-9β-PGD₁, a compound according to claim
 17. 19. A compound according to claim 16, wherein R₃ and R₄ are both fluoro.
 20. 2,2,16,16-Tetrafluoro-9β-PGD₁, a compound according to claim
 17. 21. A compound according to claim 12, wherein Z₇ is --(CH₂)₃ --(CH₂)_(g) --CH₂ --.
 22. A compound according to claim 21, wherein g is
 3. 23. A compound according to claim 22, wherein R₅ and R₆ are both hydrogen.
 24. A compound according to claim 23, wherein R₃ and R₄ are both hydrogen.
 25. 2a,2b-Dihomo-9β-PGD₁, a compound according to claim
 24. 26. A compound according to claim 23, wherein R₃ and R₄ are both fluoro.
 27. 2a,2b-Dihomo-16,16-difluoro-9β-PGD₁, a compound according to claim
 26. 28. A compound according to claim 21, wherein g is
 1. 29. A compound according to claim 28, wherein R₅ and R₆ are both hydrogen.
 30. A compound according to claim 29, wherein R₃ and R₄ are both hydrogen.
 31. 9β-PGD₁, a compound according to claim
 30. 32. A compound according to claim 29, wherein R₃ and R₄ are both fluoro.
 33. 16,16-Difluoro-9β-PGD₁, a compound according to claim
 32. 